Overall, data suggests the therapeutic potential of SAHA (or other specific HDAC inhibitors) in rescuing Pa-LPS induced CF-lung disease via partial induction of IL-10 (T-reg associated cytokine), while inhibiting neutrophil influx. The gene discussed is IL10; the disease is lung disorder.